Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Andreas Mock"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/f1859e8af01a499fa1a052b2529c09ae
Autor:
Andreas Mock, Maria-Veronica Teleanu, Simon Kreutzfeldt, Christoph E. Heilig, Jennifer Hüllein, Lino Möhrmann, Arne Jahn, Dorothea Hanf, Irina A. Kerle, Hans Martin Singh, Barbara Hutter, Sebastian Uhrig, Martina Fröhlich, Olaf Neumann, Andreas Hartig, Sascha Brückmann, Steffen Hirsch, Kerstin Grund, Nicola Dikow, Daniel B. Lipka, Marcus Renner, Irfan Ahmed Bhatti, Leonidas Apostolidis, Richard F. Schlenk, Christian P. Schaaf, Albrecht Stenzinger, Evelin Schröck, Daniel Hübschmann, Christoph Heining, Peter Horak, Hanno Glimm, Stefan Fröhling
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-15 (2023)
Abstract Analysis of selected cancer genes has become an important tool in precision oncology but cannot fully capture the molecular features and, most importantly, vulnerabilities of individual tumors. Observational and interventional studies have s
Externí odkaz:
https://doaj.org/article/47ffdc7c0d55467aa0a4083d56bfaa6d
Autor:
Maria‐Veronica Teleanu, Carmina T. Fuss, Nagarajan Paramasivam, Sebastian Pirmann, Andreas Mock, Christoph Terkamp, Stefan Kircher, Laura‐Sophie Landwehr, Christina Lenschow, Nicolas Schlegel, Albrecht Stenzinger, Arne Jahn, Martin Fassnacht, Hanno Glimm, Daniel Hübschmann, Stefan Fröhling, Matthias Kroiss
Publikováno v:
Molecular Oncology, Vol 17, Iss 7, Pp 1343-1355 (2023)
Parathyroid carcinoma (PC) is an ultra‐rare malignancy with a high risk of recurrence after surgery. Tumour‐directed systemic treatments for PC are not established. We used whole‐genome and RNA sequencing in four patients with advanced PC to id
Externí odkaz:
https://doaj.org/article/65702defbecb40ad800aa40dca446c3b
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Transcriptome profiling is a mainstay of translational cancer research and is increasingly finding its way into precision oncology. While bulk RNA sequencing (RNA-seq) is widely available, high investment costs and long data return time are
Externí odkaz:
https://doaj.org/article/7c2e236b9a964289887a9255d3e42a03
Autor:
Lino Möhrmann, Maximilian Werner, Małgorzata Oleś, Andreas Mock, Sebastian Uhrig, Arne Jahn, Simon Kreutzfeldt, Martina Fröhlich, Barbara Hutter, Nagarajan Paramasivam, Daniela Richter, Katja Beck, Ulrike Winter, Katrin Pfütze, Christoph E. Heilig, Veronica Teleanu, Daniel B. Lipka, Marc Zapatka, Dorothea Hanf, Catrin List, Michael Allgäuer, Roland Penzel, Gina Rüter, Ivan Jelas, Rainer Hamacher, Johanna Falkenhorst, Sebastian Wagner, Christian H. Brandts, Melanie Boerries, Anna L. Illert, Klaus H. Metzeler, C. Benedikt Westphalen, Alexander Desuki, Thomas Kindler, Gunnar Folprecht, Wilko Weichert, Benedikt Brors, Albrecht Stenzinger, Evelin Schröck, Daniel Hübschmann, Peter Horak, Christoph Heining, Stefan Fröhling, Hanno Glimm
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
The identification of molecular biomarkers in cancer of unknown primary site (CUP) cases may enable the improvement of prognosis in these patients. Here, the authors integrate whole genome/exome, transcriptome and methylome data in 70 CUP patients, r
Externí odkaz:
https://doaj.org/article/3ed8a79da7504e68a4003ab3bffbb8af
Autor:
Barak Rotblat, Andreas Mock, Jerome Fayette, Limor Cohen, Idan Cohen, Elena Voronov, Jebrane Bouaoud, Lucas Michon, Pierre Saintigny, Luc G T Morris, Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan, Avital B Shnerb, Sooraj Mathukkada, Ofra Novoplansky, Mai Badarni, Ksenia M Yegodayev, Sapir Tzadok, Libor Brezina, Andy Karabajakian, Tomer Cooks, Irit Allon, Orr Dimitstein, Benzion Joshua, Dexin Kong, Maurizio Scaltriti, Yaron Carmi, Cristina Conde-Lopez, Jochen Hess, Ina Kurth, Moshe Elkabets
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Although the mitogen-activated protein kinases (MAPK) pathway is hyperactive in head and neck cancer (HNC), inhibition of MEK1/2 in HNC patients has not shown clinically meaningful activity. Therefore, we aimed to characterize the effect o
Externí odkaz:
https://doaj.org/article/e52b0f83da384bc987314eeb1cc6f2e4
Autor:
Natalia Voronina, John K. L. Wong, Daniel Hübschmann, Mario Hlevnjak, Sebastian Uhrig, Christoph E. Heilig, Peter Horak, Simon Kreutzfeldt, Andreas Mock, Albrecht Stenzinger, Barbara Hutter, Martina Fröhlich, Benedikt Brors, Arne Jahn, Barbara Klink, Laura Gieldon, Lina Sieverling, Lars Feuerbach, Priya Chudasama, Katja Beck, Matthias Kroiss, Christoph Heining, Lino Möhrmann, Andrea Fischer, Evelin Schröck, Hanno Glimm, Marc Zapatka, Peter Lichter, Stefan Fröhling, Aurélie Ernst
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
The shattering of chromosomes is a dramatic early event in tumourigenesis and is termed chromothripsis. Here, the authors examine chromothripsis across 28 tumour types and show that 49% of cancers exhibit features of chromothripsis.
Externí odkaz:
https://doaj.org/article/bfa7b0c2c5f44dfead7de201eaa3b1b2
Autor:
Julius Moratin, Andreas Mock, Sonja Obradovic, Karl Metzger, Christa Flechtenmacher, Karim Zaoui, Stefan Fröhling, Dirk Jäger, Jürgen Krauss, Jürgen Hoffmann, Kolja Freier, Dominik Horn, Jochen Hess, Christian Freudlsperger
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Utilizing digital pathology algorithms for the objective quantification of immunohistochemical staining, this study aimed to identify robust prognostic biomarkers for oral cancer. Tissue microarrays with specimens of a large cohort of oral squamous c
Externí odkaz:
https://doaj.org/article/878ad9c234c84178bc2f6cf9c8d6d9e0
Autor:
Andreas Mock, Michaela Plath, Julius Moratin, Maria Johanna Tapken, Dirk Jäger, Jürgen Krauss, Stefan Fröhling, Jochen Hess, Karim Zaoui
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
While genetic alterations in Epidermal growth factor receptor (EGFR) and PI3K are common in head and neck squamous cell carcinomas (HNSCC), their impact on oncogenic signaling and cancer drug sensitivities remains elusive. To determine their conseque
Externí odkaz:
https://doaj.org/article/457455322d0b483b8198ecc589e06233
Autor:
Sebastian Schölch, Benedikt Brors, Albrecht Stenzinger, Ursula Ehmer, Ulrich-Frank Pape, Christoph Springfeld, Dirk Jäger, Felix J Hüttner, Andreas Mock, Christoph E Heilig, Simon Kreutzfeldt, Daniel Huebschmann, Christoph Heining, Evelin Schröck, Richard Schlenk, Hanno Glimm, Stefan Fröhling, Peter Horak, Leonidas Apostolidis, Marinela Augustin, Daniela Aust, Irfan Ahmed Bhatti, Johannes Bloehdorn, Cornelia Brendel, Christian Britschgi, Jan Braess, Stefan Burdach, Elena Busch, Jozefina Casuscelli, Alexander Desuki, Thomas Deutsch, Mareike Dietrich, Thomas J Ettrich, Johanna Falkenhorst, Tanja Fehm, Anne Flörcken, Andrea Forschner, Stefan Fuxius, Maria Gonzales-Carmona, Frank Griesinger, Sabine Grill, Stefan Gröschel, Georg Martin Haag, Ulrich Haag, Niels Halama, Holger Hebart, Nina Heidger, Barbara Hermes, Georg Hess, Simone Hettmer, Manuela Hoechstetter, Martin Hoffmann, Anna L Illert, Maximilian Jenzer, Bernd Kasper, Stefan Kasper-Virchow, Thomas Kindler, Ewa Koscielniak, Jan Krönke, Michael Kühn, Volker Kunzmann, Alois Lang, Jonas Leichsenring, Elisabeth Livingstone, Lucia Liotta, Kim Luley, Elisabeth Mack, Uwe M Martens, Klaus Metzeler, Jan Moritz Middeke, Lino Möhrmann, Roopa Jayarama-Naidu, Lukas Perkhofer, Arne Pfeufer, Constantin Pixberg, Michael Quante, Bernhard Rendenbach, Damian Rieke, Christian Rothermundt, Andre Norbert Sagerer, Martin Salzmann, Dieter Saur, Bastian Schilling, Jan Schleicher, Anke Schlenska-Lange, Thomas Schmidt, Sophia Schmitz, Rajiv Shah, Khalid Shoumariyeh, Alexander Siebenhüner, Martin Singh, Jens Siveke, Helen Starke, Sophia Strobel, Veronica Teleanu, Niklas Thon, Sebastian Wagner, Thomas Walle, Benedikt Westphalen, Bettina Whitlock, Eva Winkler, Naita Maren Wirsik, Lena Woydack, Angelika Zabel-du Bois, Stefanie Zschäbitz
Publikováno v:
ESMO Open, Vol 4, Iss 6 (2019)
Objective Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecul
Externí odkaz:
https://doaj.org/article/0122f1ac148444cbaeb951db5af876a5